"L'émerveillement est la source de l'imaginaire."
- Sol et Gobelet
Dr. Mathieu Lupien is a senior scientist at the Princess Margaret Cancer Centre and is an associate professor in the Department of Medical Biophysics at the University of Toronto. He also has a cross-appointment with the Ontario Institute for Cancer Research (OICR). He earned his Ph.D. at McGill University (Montreal, Canada) in 2005, followed by post-doctoral training in medical oncology at the Dana-Farber Cancer Institute, Harvard Medical School (Boston, MA) as an Era of Hope fellow.
Dr. Lupien completed his post-doctoral training in 2008 and was recruited as a faculty member at the Dartmouth Medical School (Hanover, NH) in 2009, where he became Director of the Quantitative Epigenomics Laboratory before moving to Princess Margaret Cancer Centre in 2012.
Dr. Lupien is recognized for three seminal discoveries: 1- Epigenetic modifications on histones can discriminate cell-type-specific-noncoding gene regulatory elements in normal and cancer cells; 2- Epigenetic alterations at gene regulatory elements underlie cancer initiation and progression; 3- Noncoding genetic alterations promoting cancer development preferentially target gene regulatory elements. Overall, Dr. Lupien’s research highlights the need to characterize and understand the role of noncoding regulatory elements as targets of genetic and epigenetic changes in oncogenesis.
Among other honours, Dr. Lupien is a recipient of the Investigator Award from the OICR, the New Investigator Salary Award from CIHR, The Rising Star in Prostate Cancer Research award from PCC/Movember, the Till and McCulloch Discovery of the Year award and the Canadian Cancer Society Bernard and Francine Dorval Award for Excellence.